Rafeh Naqash A, Yang LV, Sanderlin EJ, Atwell DC, Walker PR. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. AO [Internet]. 2018 May 4 [cited 2025 Feb. 17];57(5):705-8. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/24771